• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Butterfly Network Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    5/1/24 4:12:16 PM ET
    $BFLY
    Medical Electronics
    Health Care
    Get the next $BFLY alert in real time by email
    0001804176false0001804176us-gaap:WarrantMember2024-04-262024-04-260001804176us-gaap:CommonClassAMember2024-04-262024-04-2600018041762024-04-262024-04-26

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 26, 2024

    Butterfly Network, Inc.

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

    001-39292

    84-4618156

    (State or other jurisdiction of
    incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

    ​

    1600 District Avenue
    Burlington, MA

    ​
    01803

    (Address of principal executive offices)

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (781) 557-4800

    Not applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    ​

    Trading Symbol(s)

    ​

    Name of each exchange on which registered

    Class A common stock, par value $0.0001 per share

    ​

    BFLY

    ​

    The New York Stock Exchange

    Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share

    ​

    BFLY WS

    ​

    The New York Stock Exchange

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company         ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    Item 2.02.    Results of Operations and Financial Condition.

    On May 1, 2024, Butterfly Network, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2024 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 hereto.

    The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing

    Item 3.01.    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On April 26, 2024, the Company received a notification letter (the “Notice”) from the New York Stock Exchange (the “NYSE”) advising that because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period, it is not in compliance with Section 802.01C of the NYSE Listed Company Manual (“Section 802.01C”). The Company’s common stock will continue to be listed and traded on the NYSE, subject to the Company’s compliance with other NYSE continued listing standards.

    Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum price criteria. The Company will notify the NYSE within 10 business days of its receipt of the Notice of its intent to cure the deficiency. The Company may regain compliance with the minimum price criteria at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The Company intends to consider all available alternatives to regain compliance within the six-month cure period and will pursue those alternatives that are in the best interest of the Company and its shareholders.

    The Notice does not affect the ongoing business operations of the Company or its reporting requirements with the Securities and Exchange Commission.

    As required by Section 802.01C, the Company issued a press release on May 1, 2024, along with its results of operations announcing that it had received the Notice. A copy of the press release is furnished herewith as Exhibit 99.1.

    Item 9.01    Financial Statements and Exhibits.

    (d)

    Exhibits.

    Exhibit No.

        

    Description

    99.1

     

    Press Release dated May 1, 2024

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    ​

    ​

    ​

    Forward-Looking Statements

    Certain statements, estimates, targets and projections in this Current Report on Form 8-K may constitute “forward-looking statements” within the meaning of the federal securities laws. The words “anticipate,” “believe,” continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding the Company’s or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are

    ​

    cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. the Company gives no assurance that any expectations set forth in this Current Report on Form 8-K will be achieved. Various risks and uncertainties (some of which are beyond the Company’s control) or other factors could cause actual future results, performance or events to differ materially from those described herein. Some of the factors that may impact future results and performance may include, without limitation: the Company’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, the Company’s ability to continue to comply with applicable listing standards of the NYSE, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in other filings that the Company makes with the Securities and Exchange Commission. These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.

    ​

    ​

    ​

    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

     

        

    BUTTERFLY NETWORK, INC.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    By:

    /s/ Heather C. Getz, CPA

    ​

    ​

    Name:

    Heather C. Getz, CPA

    ​

    ​

    Title:

    Executive Vice President and Chief Financial & Operations Officer

    ​

    ​

    ​

    ​

    Date: May 1, 2024

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Get the next $BFLY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFLY

    DatePrice TargetRatingAnalyst
    3/17/2025Outperform
    William Blair
    9/10/2024$3.00Buy
    Lake Street
    3/29/2023$2.25Neutral
    UBS
    11/29/2022$4.50Outperform
    Oppenheimer
    10/4/2022$9.50Buy
    B. Riley Securities
    12/17/2021$7.00Neutral
    UBS
    More analyst ratings

    $BFLY
    SEC Filings

    See more
    • SEC Form 144 filed by Butterfly Network Inc.

      144 - Butterfly Network, Inc. (0001804176) (Subject)

      5/5/25 3:27:27 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • SEC Form 10-Q filed by Butterfly Network Inc.

      10-Q - Butterfly Network, Inc. (0001804176) (Filer)

      5/2/25 7:28:43 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Butterfly Network, Inc. (0001804176) (Filer)

      5/2/25 7:25:19 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Butterfly Network's RoHS Lead Exemption Revocation Request Progresses to Stakeholder and Consultant Assessment

      Oeko-Institut appointed for third-party evaluation; stakeholder consultation will run June 6, 2025 - August 1, 2025 Butterfly Network, Inc. ("Butterfly", "the Company") (NYSE:BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced that the European Commission has officially initiated the review and stakeholder consultation period for the Company's request to revoke Annex IV n. 14 of the European Commission's Restriction of Hazardous Substances (RoHS) Directive – a temporary exemption historically granted for lead in single crystal piezoelectric materials for ultrasonic transducers. Following Butterfly's revocation submission in October 202

      6/9/25 8:00:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc.

      6/4/25 2:36:00 PM ET
      $BFLY
      $MDT
      $ORCL
      $RXRX
      Medical Electronics
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Computer Software: Prepackaged Software
    • Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders

      Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigham—where AI models identified cancer survival outcomes using facial photographs—as evidence that healthcare may become AI's "most profound application." As adoption moves from theory to practice, several tech and biotech players are already making real-world strides. Recent developments have come from Avant Technologies, Inc. (OTCQB:AVAI), Butterfly N

      5/27/25 9:45:00 AM ET
      $ATR
      $AZN
      $BFLY
      $RLAY
      Plastic Products
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & COO Getz Heather C sold $144,069 worth of shares (65,456 units at $2.20), decreasing direct ownership by 2% to 2,919,274 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      5/7/25 4:18:53 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • President & CEO Devivo Joseph sold $780,684 worth of shares (320,215 units at $2.44), decreasing direct ownership by 4% to 7,249,789 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      4/29/25 5:40:11 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Chief Technology Officer Stoica Andrei G sold $3,908 worth of shares (1,805 units at $2.17), decreasing direct ownership by 0.11% to 1,600,182 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      4/3/25 5:24:38 PM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robbins Larry bought $262,251 worth of shares (244,774 units at $1.07) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      9/4/24 4:34:48 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Director Robbins Larry bought $1,683,373 worth of shares (1,676,869 units at $1.00) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      8/30/24 4:18:35 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • President & CEO Devivo Joseph bought $98,519 worth of shares (104,000 units at $0.95), increasing direct ownership by 2% to 7,009,221 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      8/7/24 4:34:48 PM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Financials

    Live finance-specific insights

    See more
    • Butterfly Network to Report First Quarter 2025 Financial Results on May 2, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report first quarter 2025 financial results on May 2, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on May 2 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Eve

      4/17/25 4:05:00 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast before the market opens on February 28 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly

      2/18/25 8:05:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network Reports Third Quarter 2024 Financial Results

      Delivered Quarterly Revenue of $20.6mm, 33% YoY Growth Raises Full Year Revenue and Adjusted EBITDA Guidance Delivered quarterly Revenue of $20.6 million in Q3, representing 33% YoY growth Reduced Q3 Net Loss by 38% and Net Cash Used in Operations by 50% Launched iQ3 in Europe and opened new markets in Indonesia, the Netherlands, and Belgium Announced the formation of Octiv™, a wholly owned subsidiary focused on bringing Butterfly's chip to new sectors Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for th

      11/1/24 6:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Leadership Updates

    Live Leadership Updates

    See more
    • Butterfly Network Appoints Steve Cashman as Chief Business Officer

      Seasoned Healthcare Leader to Drive Growth Strategy and Amplify Continued Commercial Momentum Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced the appointment of Steve Cashman as Chief Business Officer (CBO), effective today. Cashman joins Butterfly at an exciting juncture, following the Company's successful launch of its third-generation Butterfly iQ3 and historic revenue performance in the first half of 2024. Cashman will join Butterfly's Executive Management Team, overseeing the Company's global sales, marketing, product and corporate strategy. This press release f

      9/3/24 8:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Avive Welcomes Katerina Miras as Vice President of Marketing

      SAN FRANCISCO, Aug. 20, 2024 /PRNewswire/ -- Avive Solutions, Inc., a manufacturer of innovative Automated External Defibrillators (AEDs) and software solutions to improve access to AEDs and response to cardiac arrest emergencies, is excited to announce the appointment of Katerina Miras as their Vice President of Marketing. A visionary marketing leader with extensive experience in medtech, Miras brings a wealth of expertise in creating memorable healthcare brands that accelerate commercial growth. "I am honored to join Avive's leadership team at such a transformative time for

      8/20/24 9:00:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties

    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Butterfly Network

      William Blair initiated coverage of Butterfly Network with a rating of Outperform

      3/17/25 7:23:53 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Lake Street initiated coverage on Butterfly Network with a new price target

      Lake Street initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

      9/10/24 8:07:39 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • UBS initiated coverage on Butterfly Network with a new price target

      UBS initiated coverage of Butterfly Network with a rating of Neutral and set a new price target of $2.25

      3/29/23 7:12:28 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      9/3/24 7:10:06 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      8/30/24 4:05:41 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Butterfly Network Inc.

      SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

      7/8/24 4:32:42 PM ET
      $BFLY
      Medical Electronics
      Health Care